scholarly journals ABORDAGENS TERAPÊUTICAS NO TRATAMENTO DE TUNGÍASE: UMA REVISÃO DE LITERATURA

2021 ◽  
Author(s):  
Rayane Larissa de Melo Viana ◽  
Maíza Radely Pereira Ferreira ◽  
José Luiz Gustavo De Melo Viana
Keyword(s):  
Drug Therapy ◽  
Treatment Plant ◽  
Therapeutic Use ◽  
Plant Oils ◽  
America Latina ◽  
Therapy Treatment

Introdução: A tungíase é uma doença infecciosa causada por uma pulga ectoparasita da ordem Siphonatera, gênero Tunga e pela espécie penetrans, podendo atingir humanos e animais, sendo endêmica na América Latina, África, Índia, Caribe e tendo seu período de proliferação durante estação quente e seca. Essa patologia constitui um problema de saúde pública visto que ocorre com frequência em países em desenvolvimento, especialmente naqueles em que populações marginalizadas não tem acesso a condições de saneamento básico e saúde. Objetivos: realizar uma revisão de literatura acerca das abordagens terapêuticas utilizadas no tratamento de tungíase. Metodologia: foi realizado uma busca, em outubro de 2020, utilizando-se base de dados como PubMed, Cochrany Library e Lilacs, sintaxe com os seguintes descritores: tungiasis, tunga, drug therapy, treatment, plant oils, therapeutic use. Foram identificados 63 artigos, selecionados artigos independentes do idioma, limite temporal entre 2009 a 2019, encontrados na íntegra e que retratassem tratamento em humanos, como critérios de exclusão, estudos com animais, e metodologia incompleta. Desse modo, foram eleitos 13 artigos. Resultados: em um estudo no nordeste brasileiro, fatores ambientais influenciam na disseminação da tungíase somado à precariedade da população, favorecendo surtos da doença. Em uma comunidade do Quênia, foi realizado um ensaio clínico randomizado com óleo de coco e permanganato de potássio, o tratamento com os óleos foi mais eficaz, pois reduziu o nível de inflamação, dor e coceira. Somado a isso, um estudo mais recente, evidencia, através de ensaio clínico randomizado, que o uso de sapatos tem efeito protetor e o uso de óleos é preventivo na infestação. Conclusão: a utilização de óleos no tratamento da prevenção da tungíase mostrou-se eficaz, além de ser uma forma acessível a população, além de não oferecer riscos com a retirada manual da pulga.

scholarly journals Telemonitorização de sintomas pós quimioterapia com dispositivos mobile: revisão integrativa da literatura

2021 ◽  
Vol 10 (10) ◽  
pp. e586101019188
Author(s):  
Eduardo Tadeu Azevedo Moura ◽  
Jemima Silva Inocêncio ◽  
André da Silva Sant’Ana ◽  
Adicinéia Aparecida de Oliveira ◽  
Silvia de Magalhães Simões
Keyword(s):  
Drug Therapy ◽  
Mobile Health ◽  
Cancer Care ◽  
Medical Oncology ◽  
Mobile App ◽  
Mobile Game ◽  
Chemotherapy Drug ◽  
Cancer Care Facilities ◽  
Care Facilities ◽  
Therapy Treatment

O objetivo desse estudo foi avaliar se há benefícios no telemonitoramento de sintomas pós quimioterapia com dispositivos mobile em comparação com modelo tradicional de visitas médicas intervalares no cuidado de pacientes oncológicos, de modo a propiciar ganhos em desfechos prioritários para paciente. Trata-se de uma revisão integrativa de artigos publicados no Pubmed e Scielo nos últimos cinco anos. Termos de busca incluíram cancer, neoplasia, neoplasms, oncology, medical oncology, cancer care facilities, oncology service, telemedicine, telemonitoring, teleoncology, mobile health, mhealth, m-health, e-health, ehealth, videogame, mobile game, mobile app, app-technology, chemotherapy, drug therapy, treatment, drug therapy. Foram incluídos estudos randomizados e controlados, publicados em língua inglesa, pacientes oncológicos expostos a quimioterapia, supervisionados remotamente das toxidades agudas induzidas por quimioterapia, com os dados inseridos por dispositivos mobile. Para extração de dados, dois revisores utilizaram ficha com campos de informação padronizados. Os estudos analisados após critérios de elegibilidade apontam melhor controle de sintomas e desfechos. Conclui-se que telemonitorar toxidade pós quimioterapia por meio de dispositivos mobile gera melhor controle de sintomas e reduz complicações.

scholarly journals TREATMENT OF INFANTILE FACE HEMANGIOMAS WITH PROPRANOLOL

2019 ◽  
Vol 23 (5) ◽  
pp. 212-216
Author(s):  
Ilya Vyacheslavovich Stepanov ◽  
D. Yu Haritonov ◽  
I. V Korytina ◽  
M. A Agapova ◽  
A. V Podoprigora
Keyword(s):  
Drug Therapy ◽  
Tumor Volume ◽  
Beta Blockers ◽  
Combined Treatment ◽  
Vascular Tumors ◽  
Active Therapy ◽  
Direct Indication ◽  
To Receive ◽  
Therapy Treatment ◽  
Area And Volume

The aim of the study was to increase the effectiveness of treatment of facial hemangiomas in children because of the usage of non-selective beta-blocker - propranolol in complex treatment. Materials and methods of research. 18 children under the age of 1 year with maxillofacial hemangiomas were observed. Localized hemangioma was observed in 38.8% (n=7). In 44.4% (n=8) hemangiomas occupied 2-3 adjacent anatomical areas. In 16.8% (n=3) hemangioma occupied more than 3 anatomical areas. For drug therapy of facial hemangiomas in children, non-selective beta - blockers - «Propranolol»were used. Results. The minimum course of treatment was 6 months, the average - 9 months, the maximum - 13. Treatment was completed in 11 (61.1%) children, 4 of them (22.2%) had involution of education. 2 (11.1%) were operated after a course of therapy of betablockers. 5 (27.8%), after 12 months of photothermolysis. Another 5 (27.8%) continue to receive drug therapy with non-selective beta-blockers to date. there is a positive dynamics, consisting in persistent degradation of tumor volume. All children had a significan t decrease in the area and volume of hemangioma. Summary. Localization of vascular tumors in the maxillofacial region, rapid growth, leading to irreversible functional and aestheti c disorders - is a direct indication for active therapy. Treatment of facial hemangiomas in children with non-selective beta-blockers as an independent method refers to the method of choice, in case of impossibility or high risk of surgical treatment, or is part of the combined treatment.

scholarly journals Targeted drug therapy for meningiomas

2007 ◽  
Vol 23 (4) ◽  
pp. E12 ◽  
Author(s):  
Andrew D. Norden ◽  
Jan Drappatz ◽  
Patrick Y. Wen
Keyword(s):  
Radiation Therapy ◽  
Drug Therapy ◽  
Conventional Therapy ◽  
Chemotherapeutic Agents ◽  
Molecular Therapies ◽  
Targeted Molecular Therapies ◽  
Targeted Drug ◽  
Minimal Benefit ◽  
Therapy Treatment

✓ Although advances in surgery, radiation therapy, and stereotactic radiosurgery have significantly improved the treatment of meningiomas, there remains an important subset of patients whose tumors are refractory to conventional therapy. Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed.

scholarly journals 551. Enhancement of Gene Therapy Treatment for Sandhoff Disease Through Complimentary Drug Therapy

2016 ◽  
Vol 24 ◽  
pp. S221
Author(s):  
Evan J.R. Woodley ◽  
Karlaina Osmon ◽  
Patrick Thompson ◽  
Subha Karumuthil-Melethil ◽  
Steven Gray ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Drug Therapy ◽  
Sandhoff Disease ◽  
Therapy Treatment

scholarly journals Leprosy: Cause, Symptons and Treatment.

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
Mohit Kumar Tiwari ◽  
Pratibha Gupta
Keyword(s):  
Drug Therapy ◽  
Communicable Disease ◽  
Mycobacterium Leprae ◽  
Medical System ◽  
The Body ◽  
Body Parts ◽  
Therapy Treatment

Leprosy is considerd to be a very severe degenerative and communicable disease since long. This disease is caused by bacillus Mycobacterium leprae or Mycobacterium leprometosis or Mycobacterium leprimurium, which is expressed as nodes on the body or degeneration of body parts especially of hand and legs. There is a detailed description of symptoms and treatment of leprosy in ancient Ayurvedic medical litrature. In morden medical system multi drug therapy treatment is used, combining Rifampcin, Ofloxcin and Minocycline antibiotics which are very effective. Inspite of that in Indian sub continent very effective results were not found due to lack of awareness and education, although improvement is visible now.

Patient surveys for cancer populations: Initial experiences with Cancer CAHPS.

2016 ◽  
Vol 34 (7_suppl) ◽  
pp. 281-281
Author(s):  
Manasi Tirodkar ◽  
Mark W Friedberg ◽  
Shelley Fuld Nasso ◽  
Lindsey M Roth ◽  
Aaron Smith-McLallen ◽  
...  
Keyword(s):  
Decision Making ◽  
Drug Therapy ◽  
Cancer Patients ◽  
Shared Decision Making ◽  
Claims Data ◽  
Patient Experiences ◽  
Shared Decision ◽  
Communication Score ◽  
Adjusted Scores ◽  
Therapy Treatment

281 Background: Patient experiences are an important component of quality, but information on how well oncology providers meet the specific needs of patients with cancer is limited. This study reports on the patient experiences among patients undergoing drug therapy treatment for cancer in diverse outpatient settings. Methods: We assessed patient experiences using a modified version of the CAHPS Survey for Cancer Caredeveloped by the American Institutes for Research.The survey has five composites and an overall rating of providers. We used claims data from an insurance plan in Southeastern Pennsylvania to identify all patients who had a paid claim for drug therapy treatment at 26 practices from January 1 through July 31, 2014. The survey was sent to 2,302 patients who met this criteria and 701 patients returned a completed survey for a response rate of 31%. We calculated scores of 0-100 on the composites after adjusting for age, education, self-rating of mental health and response tendency (a measure of level of optimism/pessimism). Results: In general, cancer patients rated their providers highly on patient experience, particularly on access and communication. However, cancer patients rated their providers lower on shared decision-making and helping patients manage their symptoms and care at home. The scaled, adjusted scores on the five composites were: Access (score=91; 95% CI=90-92); Affective communication (score=90; 95% CI=88-91); Exchanging information/keeping patients up to date (score=89; 95% CI=88-90); Shared decision-making (score=78; 95% CI=76-80); Enabling patient self-management (score=69; 95% CI=67-71). We encountered several challenges in fielding the survey related to attributing patients to specific practice sites, identifying patients who had died, and concerns raised by patients/family respondents about the length or content of the survey. Conclusions: Our findings suggest the need for strong efforts to engage cancer patients in decision-making and provide supportive care. Methodology for sampling patients using claims data needs to be more accurate and the survey could be edited for length and comprehension.

Sign in / Sign up

Export Citation Format

Share Document